Medical University of Vienna

Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth.

A novel pilot study demonstrates that respiratory function monitoring (RFM) significantly reduces the number of attempts needed for successful supraglottic airway device placement in neonates, including those under 1500g.

A phase II pilot trial investigated very low doses of rituximab in patients with autoimmune hemolytic anemia (AIHA) to suppress CD20+ cell counts.

The major adverse cardiac events (MACE) endpoint, a long-standing standard in cardiovascular trials, is being questioned for its clinical relevance.